Company News

Company News
September 01, 2022
Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
Vancouver, British Columbia, Canada – September 1 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
August 30, 2022
Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction
Vancouver, British Columbia, Canada - August 30, 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (FWB: LD6,...
Read more
Company News
August 26, 2022
Core One Labs Engages in Talks with GMP Manufacturing Partner for Commercial Scale Production of Proprietary Biosynthetic Psilocybin
Vancouver, British Columbia, Canada – August 26, 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”...
Read more
Company News
August 19, 2022
Core One Labs’ Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies
Vancouver, British Columbia, Canada – August 19, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
August 18, 2022
Core One Labs’ Akome Achieves Significant Research Milestone with Positive Neurogenesis Stimulation Studies Results
Core One Labs’ Akome Achieves Significant Research Milestone with Positive Neurogenesis Stimulation Studies Results Opening the Door to Expanded Patent Coverage Vancouver,...
Read more
Company News
August 15, 2022
Core One Labs’ Vocan Successfully Converts Psilocin Precursor into Psilocybin
Vancouver, British Columbia, Canada – August 15, 2022 – Further to its press release dated August 12, 2022, Core One Labs Inc. (CSE: COOL), (OTC: Read more